Ionis Pharmaceuticals Inc

NASDAQ:IONS   4:00:00 PM EDT
40.32
+0.12 (+0.30%)
7:52:06 PM EDT: $39.94 -0.38 (-0.94%)
Earnings Announcements

Ionis Announces Positive Results From Fesomersen Development Program

Published: 11/04/2022 11:18 GMT
Ionis Pharmaceuticals Inc (IONS) - Ionis Announces Positive Results From Fesomersen Development Program.
Ionis Pharmaceuticals Inc - Ionis to Regain Rights to Fesomersen From Bayer.
Ionis Pharmaceuticals Inc - in Study, Fesomersen Achieved Its Primary Endpoint.
Ionis Pharmaceuticals Inc - Fesomersen Showed Favorable Safety and Tolerability With 48 Weeks of Treatment in Study.
Revenue is expected to be $164.5 Million
Adjusted EPS is expected to be -$0.73

Next Quarter Revenue Guidance is expected to be $148.74 Million
Next Quarter EPS Guidance is expected to be -$0.77

More details on our Analysts Page.